stoxline Quote Chart Rank Option Currency Glossary
  
Nexalin Technology, Inc. (NXL)
0.6132  -0.026 (-4.11%)    06-12 16:00
Open: 0.604
High: 0.6499
Volume: 73,641
  
Pre. Close: 0.6395
Low: 0.53
Market Cap: 5(M)
Technical analysis
2024-06-12 4:24:03 PM
Short term     
Mid term     
Targets 6-month :  1.25 1-year :  1.64
Resists First :  1.07 Second :  1.4
Pivot price 0.78
Supports First :  0.52 Second :  0.44
MAs MA(5) :  0.67 MA(20) :  0.9
MA(100) :  0.93 MA(250) :  0.68
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  5.8 D(3) :  7.7
RSI RSI(14): 29.7
52-week High :  3.4 Low :  0.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NXL ] has closed above bottom band by 24.4%. Bollinger Bands are 24.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.65 - 0.66 0.66 - 0.66
Low: 0.52 - 0.53 0.53 - 0.53
Close: 0.61 - 0.61 0.61 - 0.62
Company Description

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.

Headline News

Sat, 08 Jun 2024
Reviewing Nexalin Technology (NXL) & The Competition - Defense World

Tue, 04 Jun 2024
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th - Yahoo Finance

Thu, 30 May 2024
Nexalin Technology (NASDAQ:NXL) & Pixie Dust Technologies (NASDAQ:PXDT) Financial Survey - Defense World

Thu, 09 May 2024
Join Nexalin Technology's Exclusive Live Investor Webinar - GlobeNewswire

Thu, 25 Apr 2024
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements - Yahoo Finance

Wed, 10 Apr 2024
Nexalin Technology CEO Provides Letter to Shareholders - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 0 (M)
Shares Float 7 (M)
Held by Insiders 5.89e+006 (%)
Held by Institutions 22.9 (%)
Shares Short 327 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -5.98e+006
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 364.8 %
Return on Equity (ttm) -85.5 %
Qtrly Rev. Growth 158860 %
Gross Profit (p.s.) 0.13
Sales Per Share 0.08
EBITDA (p.s.) -0.37
Qtrly Earnings Growth -0.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -3 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 6.87
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 72930
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android